Amendments to the Claims:

The Claim Listing below will replace all prior version of the claims in the application:

Claim Listing

1. (Original) A compound having the formula:



or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein:

A is selected from the group consisting of:

phenyl, pyridyl, pyrazinyl, pyrimidinyl, and pyridazinyl;

B is selected from the group consisting of:

phenyl, pyridyl, pyrazinyl, pyrimidinyl, and pyridazinyl;

Het-CH_2-R^3 is selected from the group consisting of:



;

M has the formula:



wherein

L^1 is a bond or $C_{1\text{-}6}$ alkyl optionally substituted with one or more R^4 groups;

L^2 is a bond or $C_{1\text{-}6}$ alkyl optionally substituted with one or more R^4 groups;

Q is selected from the group consisting of:

a) H, b) $-NR^4R^4$, c) $-OR^4$, and d) C_{1-6} alkyl optionally substituted with one or more R^4 groups; and

W is selected from the group consisting of O and S;

X is selected from the group consisting of:

a) $-NR^4-$, b) $-NR^4NR^4-$, and c) -S-;

L is C_{1-6} alkyl optionally substituted with one or more R^4 groups;

R^1, at each occurrence, independently is selected from the group consisting of:

a) F, b) Cl, c) Br, d) I, e) $-CF_3$, f) $-OR^7$, g) -CN, h) $-NO_2$, i) $-NR^7R^7$, j) $-C(O)R^7$, k) $-C(O)OR^7$, l) $-OC(O)R^7$, m) $-C(O)NR^7R^7$, n) $-NR^7C(O)R^7$, o) $-OC(O)NR^7R^7$, p) $-NR^7C(O)OR^7$, q) $-NR^7C(O)NR^7R^7$, r) $-C(S)R^7$, s) $-C(S)OR^7$, t) $-OC(S)R^7$, u) $-C(S)NR^7R^7$, v) $-NR^7C(S)R^7$, w) $-OC(S)NR^7R^7$, x) $-NR^7C(S)OR^7$, y) $-NR^7C(S)NR^7R^7$, z) $-C(NR^7)R^7$, aa) $-C(NR^7)OR^7$, bb) $-OC(NR^7)R^7$, cc) $-C(NR^7)NR^7R^7$, dd) $-NR^7C(NR^7)R^7$, ee) $-OC(NR^7)NR^7R^7$, ff) $-NR^7C(NR^7)OR^7$, gg) $-NR^7C(NR^7)NR^7R^7$, hh) $-S(O)_pR^7$, ii) $-SO_2NR^7R^7$, and jj) R^7;

R^2, at each occurrence, independently is selected from the group consisting of:

a) F, b) Cl, c) Br, d) I, e) $-CF_3$, f) $-OR^7$, g) -CN, h) $-NO_2$, i) $-NR^7R^7$, j) $-C(O)R^7$, k) $-C(O)OR^7$, l) $-OC(O)R^7$, m) $-C(O)NR^7R^7$, n) $-NR^7C(O)R^7$, o) $-OC(O)NR^7R^7$, p) $-NR^7C(O)OR^7$, q) $-NR^7C(O)NR^7R^7$, r) $-C(S)R^7$, s) $-C(S)OR^7$, t) $-OC(S)R^7$, u) $-C(S)NR^7R^7$, v) $-NR^7C(S)R^7$, w) $-OC(S)NR^7R^7$, x) $-NR^7C(S)OR^7$, y) $-NR^7C(S)NR^7R^7$, z) $-C(NR^7)R^7$, aa) $-C(NR^7)OR^7$, bb) $-OC(NR^7)R^7$, cc) $-C(NR^7)NR^7R^7$, dd) $-NR^7C(NR^7)R^7$, ee) $-OC(NR^7)NR^7R^7$, ff) $-NR^7C(NR^7)OR^7$, gg) $-NR^7C(NR^7)NR^7R^7$, hh) $-S(O)_pR^7$, ii) $-SO_2NR^7R^7$, and jj) R^7;

R^3 is selected from the group consisting of:

a) $-OR^7$, b) $-NR^7R^7$, c) $-C(O)R^7$, d) $-C(O)OR^7$, e) $-OC(O)R^7$, f) $-C(O)NR^7R^7$, g) $-NR^7C(O)R^7$, h) $-OC(O)NR^7R^7$, i) $-NR^7C(O)OR^7$, j) $-NR^7C(O)NR^7R^7$,

k) -C(S)R^7, l) -C(S)OR^7, m) -OC(S)R^7, n) -C(S)NR^7R^7, o) –NR^7C(S)R^7,

p) -OC(S)NR^7R^7, q) –NR^7C(S)OR^7, r) –NR^7C(S)NR^7R^7, s) -C(NR^7)R^7,

t) -C(NR^7)OR^7, u) -OC(NR^7)R^7, v) -C(NR^7)NR^7R^7, w) -NR^7C(NR^7)R^7,

x) -OC(NR^7)NR^7R^7, y) –NR^7C(NR^7)OR^7, z) –NR^7C(NR^7)NR^7R^7, aa) -$S(O)_pR^7$,

bb) -SO_2NR^7R^7, and cc) R^7;

R^4, at each occurrence, independently is selected from the group consisting of:

a) H, b) =O, c) =S, d) =NR^5, e) =NOR^5, f) =N-NR^5R^5, g) –OR^5, h) -NO_2, i) -NR^5R^5,

j) -C(O)R^5, k) -C(O)OR^5, l) -OC(O)R^5, m) -C(O)NR^5R^5, n) -NR^5C(O)R^5,

o) -OC(O)NR^5R^5, p) -NR^5C(O)OR^5, q) -NR^5C(O)NR^5R^5, r) -C(S)R^5,

s) -C(S)OR^5, t) -OC(S)R^5, u) -C(S)NR^5R^5, v) -NR^5C(S)R^5, w) -OC(S)NR^5R^5,

x) –NR^5C(S)OR^5, y) -NR^5C(S)NR^5R^5, z) -C(NR^5)R^5, aa) -C(NR^5)OR^5,

bb) -OC(NR^5)R^5, cc) -C(NR^5)NR^5R^5, dd) -NR^5C(NR^5)R^5, ee) -OC(NR^5)NR^5R^5,

ff) -NR^5C(NR^5)OR^5, gg) -NR^5C(NR^5)NR^5R^5, hh) -$S(O)_pR^5$, and ii) R^5;

R^5, at each occurrence, independently is selected from the group consisting of:

a) H, b) $C_{1\text{-}6}$ alkyl, c) -C(O)-$C_{1\text{-}6}$ alkyl, and d) -C(O)O-$C_{1\text{-}6}$ alkyl,

wherein any of b) – d) optionally is substituted with one or more R^6 groups;

R^6, at each occurrence, independently is selected from the group consisting of:

a) –OH, b) –O$C_{1\text{-}6}$ alkyl, c) -SH, d) -NO_2, e) –NH_2, f) -NH$C_{1\text{-}6}$ alkyl,

g) -N($C_{1\text{-}6}$ alkyl)$_2$, h) –C(O)H, i) –C(O)OH, j) -C(O)$C_{1\text{-}6}$ alkyl,

k) -OC(O)$C_{1\text{-}6}$ alkyl, l) -C(O)O$C_{1\text{-}6}$ alkyl, m) -C(O)NH_2, n) –C(O)NH$C_{1\text{-}6}$ alkyl,

o) -C(O)N($C_{1\text{-}6}$ alkyl)$_2$, p) -NHC(O)$C_{1\text{-}6}$ alkyl, and q) -$S(O)_pC_{1\text{-}6}$ alkyl;

R^7, at each occurrence, independently is selected from the group consisting of:

a) H, b) $C_{1\text{-}6}$ alkyl, c) $C_{2\text{-}6}$ alkenyl, d) $C_{2\text{-}6}$ alkynyl, e) $C_{3\text{-}14}$ saturated, unsaturated, or aromatic carbocycle, f) 3-14 membered saturated, unsaturated, or aromatic heterocycle comprising one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, g) -C(O)-$C_{1\text{-}6}$ alkyl, h) -C(O)-$C_{2\text{-}6}$ alkenyl, i) –C(O)-$C_{2\text{-}6}$ alkynyl, j) -C(O)-$C_{3\text{-}14}$ saturated, unsaturated, or aromatic carbocycle, k) -C(O)-3-14 membered saturated, unsaturated, or aromatic heterocycle comprising one or more heteroatoms selected from the group consisting of nitrogen, oxygen,

and sulfur, l) -C(O)O-C_{1-6} alkyl, m) -C(O)O-C_{2-6} alkenyl,
n) –C(O)O-C_{2-6} alkynyl, o) -C(O)O-C_{3-14} saturated, unsaturated, or aromatic carbocycle, and p) -C(O)O-3-14 membered saturated, unsaturated, or aromatic heterocycle comprising one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur,

wherein any of b) – p) optionally is substituted with one or more R^8 groups;

R^8, at each occurrence, is independently selected from the group consisting of:

a) F, b) Cl, c) Br, d) I, e) =O, f) =S, g) =NR^9, h) =NOR^9, i) =N-NR^9R^9, j) -CF_3, k) –OR^9, l) -CN, m) -NO_2, n) –NR^9R^9, o) -C(O)R^9, p) -C(O)OR^9, q) -OC(O)R^9, r) -C(O)NR^9R^9, s) –NR^9C(O)R^9, t) -OC(O)NR^9R^9, u) –NR^9C(O)OR^9, v) -NR^9C(O)NR^9R^9, w) -C(S)R^9, x) -C(S)OR^9, y) -OC(S)R^9, z) -C(S)NR^9R^9, aa) -NR^9C(S)R^9, bb) -OC(S)NR^9R^9, cc) –NR^9C(S)OR^9, dd) –NR^9C(S)NR^9R^9, ee) -C(NR^9)R^9, ff) -C(NR^9)OR^9, gg) -OC(NR^9)R^9, hh) -C(NR^9)NR^9R^9, ii) -NR^9C(NR^9)R^9, jj) -OC(NR^9)NR^9R^9, kk) –NR^9C(NR^9)OR^9, ll) -NR^9C(NR^9)NR^9R^9, mm) -$S(O)_pR^9$, nn) -$SO_2NR^9R^9$, and oo) R^9;

R^9, at each occurrence, independently is selected from the group consisting of:

a) H, b) C_{1-6} alkyl, c) C_{2-6} alkenyl, d) C_{2-6} alkynyl, e) C_{3-14} saturated, unsaturated, or aromatic carbocycle, f) 3-14 membered saturated, unsaturated, or aromatic heterocycle comprising one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, g) -C(O)-C_{1-6} alkyl, h) -C(O)-C_{2-6} alkenyl, i) –C(O)-C_{2-6} alkynyl, j) -C(O)-C_{3-14} saturated, unsaturated, or aromatic carbocycle, k) -C(O)-3-14 membered saturated, unsaturated, or aromatic heterocycle comprising one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, l) -C(O)O-C_{1-6} alkyl, m) -C(O)O-C_{2-6} alkenyl,
n) –C(O)O-C_{2-6} alkynyl, o) -C(O)O-C_{3-14} saturated, unsaturated, or aromatic carbocycle, and p) -C(O)O-3-14 membered saturated, unsaturated, or aromatic heterocycle comprising one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur,

wherein any of b) – p) optionally is substituted with one or more moieties selected from the group consisting of:

a) F, b) Cl, c) Br, d) I, e) $-CF_3$, f) –OH, g) $–OC_{1-6}$ alkyl, h) -SH,
i) $-SC_{1-6}$ alkyl, j) -CN, k) $-NO_2$, l) $–NH_2$, m) $–NHC_{1-6}$ alkyl,
n) $-N(C_{1-6}$ alkyl$)_2$, o) $-C(O)C_{1-6}$ alkyl, p) $-OC(O)C_{1-6}$ alkyl,
q) $-C(O)OC_{1-6}$ alkyl, r) $-C(O)NH_2$, s) $–C(O)NHC_{1-6}$ alkyl,
t) $-C(O)N(C_{1-6}$ alkyl$)_2$, u) $-NHC(O)C_{1-6}$ alkyl, v) $-SO_2NH_2-$,
w) $-SO_2NHC_{1-6}$ alkyl, x) $-SO_2N(C_{1-6}$ alkyl$)_2$, and
y) $-S(O)_pC_{1-6}$ alkyl;

m is 0, 1, 2, 3, or 4;

n is 0, 1, 2, 3, or 4; and

p, at each occurrence, independently is 0, 1, or 2,

and wherein the compound does not have the formula selected from the group consisting of:



,



, and



.

2. (Original) The compound according to claim 1, having the formula:



or a pharmaceutically acceptable salt, ester or prodrug thereof,

wherein A, B, L, M, R^1, R^2, R^3, X, m, and n are defined as described in claim 1.

3. (Currently amended) The compound according to claim 1 ~~or 2~~, having the formula:



or a pharmaceutically acceptable salt, ester or prodrug thereof,

wherein A, B, L, M, R^1, R^2, R^3, X, m, and n are defined as described in claim 1.

4. (Currently amended) The compound according to ~~any one of~~ claims 1~~-3~~, or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein

A is selected from the group consisting of phenyl and pyridyl;

B is selected from the group consisting of phenyl and pyridyl;

m is 0, 1, or 2; and

n is 0, 1, or 2.

5. (Currently amended) The compound according to ~~any one of claims 1-4~~ claim 4, or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein A-B is:



wherein A, R^2, and n are defined as described in claim 1.

6. (Currently amended) The compound according to claim 5, or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein A-B is:



wherein A is defined as described in claim 1.

7. (Currently amended) The compound according to claim 5, or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein A-B is:



wherein A is defined as described in claim 1.

8. (Currently amended) The compound according to ~~any one of~~ claims 1-~~7~~, or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein A-B is:



wherein B is defined as described in claim 1.

9. (Currently amended) The compound according to ~~any one of~~ claims 1-~~7~~, or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein A-B is:



wherein B is defined as described in claim 1.

10. (Currently amended) The compound according to ~~any one of~~ claims 1~~-9~~, or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein R^3 is $-NHC(O)R^7$.

11. (Currently amended) The compound according to claim 10, or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein R^3 is $-NHC(O)CH_3$.

12. (Currently amended) The compound according to ~~any one of~~ claims 1~~-9~~, or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein R^3 is:



13. (Currently amended) The compound according to claim 1~~-or 2~~, having the formula:



or a pharmaceutically acceptable salt, ester or prodrug thereof,

wherein A, B, L, M, R^1, R^2, X, m, and n are defined as described in claim 1.

14. (Currently amended) The compound according to claim 1~~-or 2~~, having the formula:



or a pharmaceutically acceptable salt, ester or prodrug thereof,

wherein A, L, M, R^1, R^3, X, and m are defined as described in claim 1.

15. (Original) The compound according to claim 14, having the formula:



or a pharmaceutically acceptable salt, ester or prodrug thereof,

wherein A, L, M, R^1, X, and m are defined as described in claim 1.

16. (Original) The compound according to claim 14, having the formula:



or a pharmaceutically acceptable salt, ester or prodrug thereof,

wherein L, M, R^3, and X are defined as described in claim 1.

17. (Original) The compound according to claim 16, having the formula:



or a pharmaceutically acceptable salt, ester or prodrug thereof,

wherein L, M, and X are defined as described in claim 1.

18. (Original) The compound according to claim 14, having the formula:



or a pharmaceutically acceptable salt, ester or prodrug thereof,

wherein L, M, R^3, and X are defined as described in claim 1.

19. (Original) The compound according to claim 18, having the formula:



or a pharmaceutically acceptable salt, ester or prodrug thereof,

wherein L, M, and X are defined as described in claim 1.

20. (Currently amended) The compound according to claim 1 ~~or 2~~, having the formula:



or a pharmaceutically acceptable salt, ester or prodrug thereof,

wherein A, L, M, R^1, R^3, X, and m are defined as described in claim 1.

21. (Original) The compound according to claim 20, having the formula:



or a pharmaceutically acceptable salt, ester or prodrug thereof,

wherein A, L, M, R^1, X, and m are defined as described in claim 1.

22. (Original) The compound according to claim 20, having the formula:



or a pharmaceutically acceptable salt, ester or prodrug thereof,

wherein L, M, R^3, and X are defined as described in claim 1.

23. (Original) The compound according to claim 22, having the formula:



or a pharmaceutically acceptable salt, ester or prodrug thereof,

wherein L, M, and X are defined as described in claim 1.

24. (Original) The compound according to claim 20, having the formula:



or a pharmaceutically acceptable salt, ester or prodrug thereof,

wherein L, M, R^3, and X are defined as described in claim 1.

25. (Original) The compound according to claim 24, having the formula:



or a pharmaceutically acceptable salt, ester or prodrug thereof,

wherein L, M, and X are defined as described in claim 1.

26. (Currently amended) The compound according to ~~any one of~~ claims 1~~-25~~, or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein M is:



and R^4, at each occurrence, independently is defined as described in claim 1.

27. (Currently amended) The compound according to claim 26, or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein M is:



and R^4 is defined as described in claim 1.

28. (Currently amended) The compound according to ~~any one of~~ claims 1~~-25~~, or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein M is:



and R^4, at each occurrence, independently is defined as described in claim 1.

29. (Currently amended) The compound according to claim 28, or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein M is:



and R^4 is defined as described in claim 1.

30. (Currently amended) The compound according to ~~any one of~~ claims 1~~-29~~, or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein X is –NH-.

31. (Currently amended) The compound according to ~~any one of~~ claims 1~~-29~~, or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein X is:



32. (Original) A compound having the structure corresponding to any one of the structures listed in Table 1, or a pharmaceutically acceptable salt, ester, or prodrug thereof.

33. (Currently amended) A pharmaceutical composition comprising one or more compounds according to ~~any one of~~ claims 1~~-32~~ and a pharmaceutically acceptable carrier.

34. (Currently amended) A method of treating a microbial infection in a mammal comprising the step of administering to the mammal an effective amount of one or more compounds according to ~~any one of~~ claims 1~~-32~~.

35. (Currently amended) A method of treating a fungal infection in a mammal comprising the step of administering to the mammal an effective amount of one or more compounds according to ~~any one of~~ claims 1~~-32~~.

36. (Currently amended) A method of treating a parasitic disease in a mammal comprising the step of administering to the mammal an effective amount of one or more compounds according to ~~any one of~~ claims 1~~-32~~.

37. (Currently amended) A method of treating a proliferative disease in a mammal comprising the step of administering to the mammal an effective amount of one or more compounds according to ~~any one of~~ claims 1~~-32~~.

38. (Currently amended) A method of treating a viral infection in a mammal comprising the step of administering to the mammal an effective amount of one or more compounds according to ~~any one of~~ claims 1~~–32~~.

39. (Currently amended) A method of treating an inflammatory disease in a mammal comprising the step of administering to the mammal an effective amount of one or more compounds according to ~~any one of~~ claims 1~~–32~~.

40. (Currently amended) A method of treating a gastrointestinal motility disorder in a mammal comprising the step of administering to the mammal an effective amount of one or more compounds according to ~~any one of~~ claims 1~~–32~~.

41. (Currently amended) A method of treating a disorder in a mammal comprising the step of administering to the mammal an effective amount of one or more compounds according to ~~any one of~~ claims 1~~–32~~ thereby to ameliorate a symptom of the disorder, wherein the disorder is selected from the group consisting of:

a skin infection, nosocomial pneumonia, post-viral pneumonia, an abdominal infection, a urinary tract infection, bacteremia, septicemia, endocarditis, an atrio-ventricular shunt infection, a vascular access infection, meningitis, surgical prophylaxis, a peritoneal infection, a bone infection, a joint infection, a methicillin-resistant *Staphylococcus aureus* infection, a vancomycin-resistant *Enterococci* infection, a linezolid-resistant organism infection, and tuberculosis.

42. (Currently amended) The method according to ~~any one of~~ claims 34~~–41~~, wherein the compound is administered orally, parentally, or topically.

43. (Currently amended) A method of synthesizing a compound according to ~~any one of~~ claims 1~~–32~~.

44. (Currently amended) A medical device containing one or more compounds according to ~~any one of~~ claims 1-~~32~~.

45. (Original) The medical device according to claim 44, wherein the device is a stent.